Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$287.3MBeat by $42.3M
EPS-$5.08Miss by $3.04
Revenue estimate$245.0M
EPS estimate-$2.04

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$404.2M
EPS estimate-$0.86

Financials

Q3 2025

Income statement

See full
Revenue$287.3M+362%
Operating income-$114.0M+2.0%
Net income-$114.2M-6.8%
EPS (diluted)-$5.08-3.3%

Balance sheet

See full
Cash & equivalents$300.7M+26.5%
Total debt$377.5M+187%
Total equity$625.7M-19.5%
Total assets$1.4B+26.9%

Cash flow

See full
CapEx$857.0K+10.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$10.22B+122%
Enterprise value$10.3B+129%
P/S13.8×-46.2×

Profitability

See full
Operating margin-41.5%-20.1pp
Net margin-39%-18.9pp

Returns & leverage

See full
Return on equity-41.2%-16.7pp
Debt / equity0.6×+0.4×
Current ratio3.4×-2.5×

Segments

By segment

See full
Reportable Segment$287.3M+362%

FAQ

When did Madrigal Pharmaceuticals, Inc. report Q3 2025 earnings?
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Madrigal Pharmaceuticals, Inc. reported revenue of $287.3M and eps of $-5.08 for Q3 2025.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $245.0M by $42.3M. EPS missed the consensus estimate of $-2.04 by $3.04.
How did Madrigal Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 362.0% from $62.2M a year earlier and eps declined 3.3% from $-4.92.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-048525) and the 10-Q periodic report (0001628280-25-048559) directly on SEC EDGAR. The filing index links above go to sec.gov.